Fischer Medical Ventures Ltd (BSE: 524743), a leading medical device company listed on the Bombay Stock Exchange, is pleased to announce the successful acquisition of a landmark mixed-use property in Malacca, Malaysia. Strategically located next to the renowned Mahkota Hospital, the property comprises hotel, commercial, and retail components, and will serve as the foundation for FMV’s regional healthcare hub.
| Fischer Medical Ventures Ltd has acquired a landmark mixed-use property in Malacca, Malaysia, to establish an integrated regional healthcare hub. Strategically located next to Mahkota Hospital, the development will showcase FMV’s medical technologies and strengthen its presence in Southeast Asia’s healthcare landscape. |
This acquisition represents a key milestone in FMV’s strategic growth plan to expand its presence across the healthcare value chain. FMV intends to progressively redevelop portions of the property into integrated healthcare facilities, including health screening centers, specialist clinics, and medical suites. The development will also serve as a direct channel to showcase and distribute FMV’s advanced medical device solutions to healthcare providers and patients.
Chairman of FMV, Mr. Ravindran Govindan, commented:
“This acquisition is a strategic milestone for FMV. The property’s location—adjacent to Mahkota Hospital in a high-traffic, medically vibrant area—offers us a unique opportunity to reimagine healthcare access in the region. By integrating our innovative medical technologies directly into care environments, we are not only expanding our business reach but also contributing meaningfully to better patient outcomes.”
“This investment supports our broader vision to develop healthcare-enabled real estate assets in key regional centers across Southeast Asia. Malacca, with its strong medical tourism ecosystem and connectivity to Singapore, Indonesia and Philippines, is the ideal starting point,” he added.
The development aligns with FMV’s vision to create sustainable healthcare infrastructure that supports both clinical excellence and commercial scalability. It also serves as a platform for FMV to directly engage with healthcare professionals, patients, and institutional partners in a dynamic setting—accelerating product adoption, training, and after-sales support.
The company expects the first phase of redevelopment to commence later this year, subject to regulatory approvals and planning. FMV will work closely with local authorities, medical stakeholders, and international partners to ensure the facility complements Malacca’s role as a key medical tourism destination.
